Flag of the European Union EU Clinical Trials Register Help

Clinical trials for eu

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11,274 result(s) found for: eu. Displaying page 211 of 564.
    «« First « Previous 207  208  209  210  211  212  213  214  215  Next» Last»»
    EudraCT Number: 2010-024306-36 Sponsor Protocol Number: 1 Start Date*: 2011-04-07
    Sponsor Name:Västra Götalandsregionen
    Full Title: An exploratory study of sorafenib for patients listed for transplantation due to HCC
    Medical condition: Patients >18 years with hepatocellular carcinoma, on waiting list for liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019829 Hepatocellular carcinoma recurrent LLT
    12.1 10019830 Hepatocellular carcinoma resectable LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002853-13 Sponsor Protocol Number: EWALL-BOLD Start Date*: 2018-03-01
    Sponsor Name:Goethe Universität Frankfurt
    Full Title: Phase II trial for the treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and Bli...
    Medical condition: Patient aged 56 and 74 with CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066109 Precursor B-lymphoblastic leukemia acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000150-26 Sponsor Protocol Number: POLESTAR Start Date*: 2022-02-14
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH
    Full Title: Phase IIA trial of short-term chemotherapy and pembrolizumab, followed by Pembrolizumab and Olaparib as firstline therapy in Her-2 negative gastric/gastroesophageal-junction (GEJ) Adenocarcinoma – ...
    Medical condition: metastatic or advanced inoperable Her-2 negative esophagogastric adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2023-000382-14 Sponsor Protocol Number: mRNA-1273-P203 Start Date*: 2023-12-29
    Sponsor Name:ModernaTX, Inc.
    Full Title: A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 Years of...
    Medical condition: Coronavirus Disease 2019
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-002453-25 Sponsor Protocol Number: MERCURI-2 Start Date*: 2023-03-07
    Sponsor Name:Amsterdam UMC
    Full Title: Preoperative sodium glucose cotransporter 2 inhibitors for prevention of postoperative acute kidney injury in cardiac surgery patients – a randomized, placebo-controlled, multi-centre, phase IV cli...
    Medical condition: Cardiac Surgery-Associated Acute Kidney Injury
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10080266 Stage 1 acute kidney injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003217-11 Sponsor Protocol Number: NL82304.058.22 Start Date*: 2023-02-24
    Sponsor Name:Leiden University Medical Center
    Full Title: Standard versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes after Whipple procedure (SPARROW): a multicenter, randomized controlled trial
    Medical condition: Pancreatic head malignancy
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033614 Pancreatic carcinoma resectable LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026319 Malignant neoplasm of pancreatic duct LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008597 Cholangiocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002582-15 Sponsor Protocol Number: NerHer-1 Start Date*: 2023-03-20
    Sponsor Name:Medical University Graz
    Full Title: Phase II Study of Neratinib and Trastuzumab +/- Vinorelbine p.o. in Pre-treated Metastatic HER2-positive Breast Cancer (Ner-Her-1)
    Medical condition: Patients with histologically confirmed Human Epidermal Growth Factor Receptor 2 (HER2)-positive metastatic breast cancer (mBC) pretreated with trastuzumab, pertuzumab, and/or trastuzumab emtansine...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003325-17 Sponsor Protocol Number: P080403 Start Date*: 2008-10-24
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude ARCTIC Comparaison randomisée 1/ d'un traitement antiplaquettaire ajusté par monitoring à un traitement standard à dose fixe pour stenting coronaire avec DES, et 2/ d'un arrêt versus poursuit...
    Medical condition: Patients devant recevoir au moins un stent actif quel que soit le contexte
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052086 Coronary arterial stent insertion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-004704-19 Sponsor Protocol Number: MK-7625A-036 Start Date*: 2019-08-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
    Full Title: A Phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nos...
    Medical condition: Nosocomial pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10052596 Nosocomial pneumonia LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) EE (Trial now transitioned) Outside EU/EEA GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005001-26 Sponsor Protocol Number: 20-773/M Start Date*: 2021-12-24
    Sponsor Name:UMC Utrecht
    Full Title: Influencing Progression of Airway Disease in Primary Antibody Deficiency
    Medical condition: Primary antibody deficiency: - Unclassified antibody deficiency (unPAD) - IgA deficiency - Specific polysaccharide antibody deficiency (SPAD) - IgG subclass deficiency (IgSD) - Common variable immu...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003524-32 Sponsor Protocol Number: NEPHENTE Start Date*: 2023-01-11
    Sponsor Name:Istituti Clinici Scientifici Maugeri SpA Società Benefit
    Full Title: Neoadjuvant pembrolizumab in high-risk thyroid cancers (NEPENTHE)
    Medical condition: High-risk thyroid cancers
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10029099 Neoplasm thyroid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003440-92 Sponsor Protocol Number: INFINITY Start Date*: 2020-12-22
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: TremelImumab aNd durvalumab combination For the non-operatIve management (NOM) of Microsatellite InstabiliTY (MSI)-high resectable gastric or gastroesophageal junction cancer: The multicentre, sing...
    Medical condition: The disease under clinical investigation is represented by resectable gastric or gastroesophageal junction (Siewert II-III) adenocarcinoma staged as cT = 2, any cN, or any cT, cN1-3 (TNM classifica...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10073379 Tubular adenocarcinoma gastric LLT
    20.0 100000004864 10073378 Signet-ring cell adenocarcinoma gastric LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000417-31 Sponsor Protocol Number: IM101-473 Start Date*: 2014-07-01
    Sponsor Name:University Medical Center Groningen
    Full Title: Randomized, double-blind, placebo-controlled phase III study (ASAP III study) to assess the efficacy and safety of Abatacept treatment in patients with primary Sjögren’s syndrome (ASAP III study = ...
    Medical condition: Primary Sjögren's syndrome (pSS)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004859 10042846 Syndrome Sjogren's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004420-15 Sponsor Protocol Number: M21IDB Start Date*: 2021-11-30
    Sponsor Name:NKI-AVL
    Full Title: A Phase 2 clinical study to assess efficacy of Induction ipilimumab/nivolumab to spare the Bladder in urothelial bladder cancer (Indi-Blade)
    Medical condition: Urothelial cell carcinoma of the bladder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004987-23 Sponsor Protocol Number: RAS-Triplet Start Date*: 2020-05-22
    Sponsor Name:UMC Utrecht
    Full Title: A Dose-Escalating Phase I/II Study in Patients with RAS-Mutated Metastatic Colorectal Cancer to Investigate Safety and Clinical Activity of the Triple Combination of: MEK-inhibitor binimetinib, Pan...
    Medical condition: colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2023-000156-38 Sponsor Protocol Number: 20230123SE Start Date*: 2023-05-04
    Sponsor Name:Semmelweis University, Department of Internal Medicine and Oncology
    Full Title: Value-based health economic comparative study of subcutaneous and intravenous trastuzumab-pertuzumab for HER-2 positive metastatic breast cancer based on patient reported outcomes.
    Medical condition: HER-2 positive advanced breast cancer, locally unresectable or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004819-31 Sponsor Protocol Number: IN-CRC-001 Start Date*: 2021-05-19
    Sponsor Name:IN3BIO
    Full Title: A Phase I/II, multi-centre, open-label, adaptive design, umbrella study assessing the safety, tolerability, immunogenicity and efficacy of IN01 in combination with small-molecule inhibitors in two ...
    Medical condition: colorectal cancer at a metastatic stage, eligible for a second line treatment and presenting with a constitutive BRAF or RAS mutation
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000469-33 Sponsor Protocol Number: NL.76663.018.21 Start Date*: 2021-10-12
    Sponsor Name:Amsterdam UMC location AMC
    Full Title: A Prospective Multicenter Randomized Controlled, Open-label Study to Compare the Efficacy of Subcutaneous Infliximab Monotherapy with Subcutaneous Infliximab and Concomitant Immunosuppression in th...
    Medical condition: Crohns disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015558-40 Sponsor Protocol Number: ABACEPT1 Start Date*: 2010-07-28
    Sponsor Name:University Medical Center Groningen
    Full Title: Abatacept treatment in patients with primary Sjögren’s syndrome
    Medical condition: Sjögren’s syndrome (SS) is a chronic, systemic, lymphoproliferative autoimmune disease affecting the exocrine glands. The salivary and lacrimal glands are most commonly affected, resulting in dry m...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10040767 Sjogren's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002356-27 Sponsor Protocol Number: XCGD_MOBI1 Start Date*: 2015-10-16
    Sponsor Name:Ospedale San Raffaele
    Full Title: A multicentric, exploratory, non-randomised, non-controlled, prospective, open-label phase II, study evaluating safety and efficacy of IBU, G-CSF and Plerixafor as a stem cell mobilization regimen ...
    Medical condition: X-linked chronic granulomatous disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10008906 Chronic granulomatous disease PT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 207  208  209  210  211  212  213  214  215  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 15:02:54 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA